SIC
AKBA icon

SJS Investment Consulting’s Akebia Therapeutics AKBA Stock Holding History

SJS Investment Consulting’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$629 Buy
551
+531
+2,655% +$632 ﹤0.01% 2191
2026
Q1 		$28 Buy
+20
New +$27 ﹤0.01% 2334

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
PWP
Parkwoods Wealth Partners Syracuse, New York $622M AUM 24.36% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return

SJS Investment Consulting's AKBA Position: Q2 2026 in Review

SJS Investment Consulting increased its Akebia Therapeutics (AKBA) stake by 2,655% in Q2 2026, buying an estimated $632 and bringing the position to 551 shares worth $629. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

SJS Investment Consulting first reported a position in AKBA in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • SJS Investment Consulting held 551 shares of Akebia Therapeutics worth $629 as of Q2 2026.
  • SJS Investment Consulting bought 531 Akebia Therapeutics shares in Q2 2026, an estimated $632.
  • Akebia Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2191 holding.
  • SJS Investment Consulting first reported a position in Akebia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.